Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

At the close on September 16, 2026, GSK stock finished at 1,759,000.00 KRW on Korea Exchange with a 4.08 percent rise. It ...

Sir Keir Starmer’s decision to invite Sir Pascal Soriot, AstraZeneca’s chief executive, to Beijing at the beginning of the year was a textbook piece of modern diplomacy.

GSK will acquire a Chimagen trispecific T cell engager for multiple myeloma in a deal worth up to $750M. Here's what it means ...

Explore the latest oncology biotech news, from clinical data to fundraising and biotech deals, in our September 2026 roundup.

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...